COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SAUDI ARABIA

被引：1
|
作者：
Alhammad, A. [1 ]
Lecca, Garrido S. [2 ]
机构：
[1] King Abdul Aziz Med City, Riyadh, Saudi Arabia
[2] Bristol Myers Squibb, Dubai, U Arab Emirates
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2254
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN181
引用
收藏
页码：A741 / A741
页数：1
相关论文
共 50 条
  • [21] A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer
    Panje, C. M.
    Dedes, K. J.
    Matter-Walstra, K.
    Schwenkglenks, M.
    Gautschi, O.
    Siano, M.
    Aebersold, D. M.
    Plasswilm, L.
    Lupatsch, J. E.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (06) : 588 - 588
  • [22] Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer
    Courtney, P. Travis
    Yip, Anthony T.
    Cherry, Daniel R.
    Salans, Mia A.
    Kumar, Abhishek
    Murphy, James D.
    [J]. JAMA NETWORK OPEN, 2021, 4 (05)
  • [23] EFFECTIVENESS AND TOLERANCE OF MAINTENANCE THERAPY IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Santos, E. S.
    Belalcazar, A.
    Vazquez, A.
    Gomez, J. E.
    Raez, L. E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S97 - S97
  • [24] COST EFFECTIVENESS OF PEMETREXED/CISPLATIN (PEM/CIS) IN THE TREATMENT OF ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSQNSCLC) PATIENTS
    Winfree, K. B.
    Shah, M.
    Peterson, P.
    Gruschkus, S.
    Eaddy, M.
    Green, M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 428 - 428
  • [25] Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
    Cheng, Minyu
    Shao, Yanfei
    Li, Li
    Jiang, Menglao
    Song, Zhouye
    [J]. BMC CANCER, 2024, 24 (01)
  • [26] Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review
    Minyu Cheng
    Yanfei Shao
    Li Li
    Menglao Jiang
    Zhouye Song
    [J]. BMC Cancer, 24
  • [27] Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer
    Rosell, Rafael
    Gonzalez-Cao, Maria
    [J]. LANCET, 2021, 397 (10274): : 557 - 559
  • [28] Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
    Yang, Szu-Chun
    Kunst, Natalia
    Gross, Cary P.
    Wang, Jung-Der
    Su, Wu-Chou
    Wang, Shi-Yi
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [29] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS IPILIMUMAB VS. PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF NON-SQUAMOUS, ADVANCED NON-SMALL CELL LUNG CANCER IN THE USA
    Chen, J.
    Velcheti, V.
    Padula, W.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S342 - S342
  • [30] Maintenance chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC)
    Belalcazar, A.
    Santos, E. S.
    Gomez, J. E.
    Lopez, E.
    Raez, L. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345